Alembic Pharmaceuticals Limited (APLLTD.NS)
INR 1045.0
(-1.06%)
INR 1045.0
(-1.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 6.15 Billion INR | 80.07% |
| 2022 | 3.41 Billion INR | -34.35% |
| 2021 | 5.2 Billion INR | -54.56% |
| 2020 | 11.46 Billion INR | 38.33% |
| 2019 | 8.28 Billion INR | 41.83% |
| 2018 | 5.84 Billion INR | 41.62% |
| 2017 | 4.12 Billion INR | 2.35% |
| 2016 | 4.03 Billion INR | -43.96% |
| 2015 | 7.19 Billion INR | 154.29% |
| 2014 | 2.82 Billion INR | 20.13% |
| 2013 | 2.35 Billion INR | 42.51% |
| 2012 | 1.65 Billion INR | 26.99% |
| 2011 | 1.3 Billion INR | 52.4% |
| 2010 | 853.87 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.34 Billion INR | -24.41% |
| 2023 Q2 | 1.36 Billion INR | 13.23% |
| 2023 Q1 | 1.2 Billion INR | -20.97% |
| 2023 FY | 6.15 Billion INR | 80.07% |
| 2023 Q3 | 1.8 Billion INR | 32.14% |
| 2023 Q4 | 1.78 Billion INR | -1.24% |
| 2022 Q1 | -658.8 Million INR | -715.13% |
| 2022 Q3 | 1.21 Billion INR | -8.57% |
| 2022 Q4 | 1.52 Billion INR | 25.16% |
| 2022 FY | 3.41 Billion INR | -34.35% |
| 2022 Q2 | 1.33 Billion INR | 302.41% |
| 2021 Q1 | 1.64 Billion INR | -34.38% |
| 2021 Q2 | 1.69 Billion INR | 2.9% |
| 2021 Q3 | 1.76 Billion INR | 4.21% |
| 2021 Q4 | 107.1 Million INR | -93.93% |
| 2021 FY | 5.2 Billion INR | -54.56% |
| 2020 FY | 11.46 Billion INR | 38.33% |
| 2020 Q2 | 3.33 Billion INR | 10.59% |
| 2020 Q4 | 2.5 Billion INR | -14.31% |
| 2020 Q1 | 3.01 Billion INR | 34.2% |
| 2020 Q3 | 2.92 Billion INR | -12.24% |
| 2019 Q2 | 2.46 Billion INR | 99.05% |
| 2019 Q3 | 2.34 Billion INR | -4.91% |
| 2019 Q4 | 2.24 Billion INR | -4.08% |
| 2019 FY | 8.28 Billion INR | 41.83% |
| 2019 Q1 | 1.23 Billion INR | -0.23% |
| 2018 Q1 | 904.7 Million INR | -3.54% |
| 2018 Q2 | 2 Billion INR | 121.15% |
| 2018 Q4 | 1.24 Billion INR | -26.99% |
| 2018 Q3 | 1.69 Billion INR | -15.11% |
| 2018 FY | 5.84 Billion INR | 41.62% |
| 2017 Q3 | 1.3 Billion INR | 7.44% |
| 2017 FY | 4.12 Billion INR | 2.35% |
| 2017 Q4 | 937.9 Million INR | -28.19% |
| 2017 Q2 | 1.21 Billion INR | 82.33% |
| 2017 Q1 | 666.7 Million INR | -28.34% |
| 2016 FY | 4.03 Billion INR | -43.96% |
| 2016 Q1 | 1.03 Billion INR | 14.22% |
| 2016 Q2 | 1.19 Billion INR | 15.5% |
| 2016 Q3 | 865.5 Million INR | -27.77% |
| 2016 Q4 | 930.4 Million INR | 7.5% |
| 2015 Q4 | 908.3 Million INR | -66.3% |
| 2015 Q3 | 2.69 Billion INR | -6.72% |
| 2015 Q2 | 2.88 Billion INR | 313.42% |
| 2015 Q1 | 698.8 Million INR | -0.63% |
| 2015 FY | 7.19 Billion INR | 154.29% |
| 2014 Q3 | 706.6 Million INR | -8.55% |
| 2014 Q2 | 772.7 Million INR | 19.48% |
| 2014 Q1 | 646.7 Million INR | 5.5% |
| 2014 FY | 2.82 Billion INR | 20.13% |
| 2014 Q4 | 703.24 Million INR | -0.47% |
| 2013 FY | 2.35 Billion INR | 42.51% |
| 2013 Q4 | 612.98 Million INR | -7.03% |
| 2013 Q1 | 466.4 Million INR | 6.84% |
| 2013 Q3 | 659.3 Million INR | 6.96% |
| 2013 Q2 | 616.4 Million INR | 32.16% |
| 2012 Q4 | 436.54 Million INR | -9.56% |
| 2012 Q1 | 308.3 Million INR | 0.0% |
| 2012 FY | 1.65 Billion INR | 26.99% |
| 2012 Q2 | 424.9 Million INR | 37.82% |
| 2012 Q3 | 482.7 Million INR | 13.6% |
| 2011 FY | 1.3 Billion INR | 52.4% |
| 2010 FY | 853.87 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sigachi Industries Limited | 571.8 Million INR | -976.981% |
| Ind-Swift Limited | 142.31 Million INR | -4227.222% |
| Bajaj HealthCare Limited | -837.93 Million INR | 834.929% |
| Sakar Healthcare Limited | 116.7 Million INR | -5176.543% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 80.592% |
| Innova Captab Limited | 943.45 Million INR | -552.732% |
| Divi's Laboratories Limited | 16 Billion INR | 61.511% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -281.289% |
| Morepen Laboratories Limited | 961.59 Million INR | -540.412% |
| Mankind Pharma Limited | 19.12 Billion INR | 67.807% |
| Sequent Scientific Limited | -358.69 Million INR | 1816.859% |
| Wanbury Limited | 559.56 Million INR | -1000.537% |
| Laurus Labs Limited | 1.6 Billion INR | -283.569% |
| Nectar Lifesciences Limited | 49.95 Million INR | -12228.729% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | -30.778% |
| Alembic Limited | 2.68 Billion INR | -129.254% |
| Hikal Limited | 696 Million INR | -784.799% |
| Neuland Laboratories Limited | 3 Billion INR | -105.219% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | -11.435% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 141.009% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -358.097% |
| Themis Medicare Limited | 435.23 Million INR | -1314.904% |
| RPG Life Sciences Limited | 876.6 Million INR | -602.51% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 84.044% |
| Lupin Limited | 19.14 Billion INR | 67.834% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -1269.323% |
| Wockhardt Limited | -4.63 Billion INR | 233.006% |
| Vaishali Pharma Limited | 7.18 Million INR | -85561.427% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -183.916% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -2641.486% |
| Jubilant Pharmova Limited | 771 Million INR | -698.729% |
| FDC Limited | 3.05 Billion INR | -101.76% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 88.941% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -4117.541% |
| Eris Lifesciences Limited | 3.91 Billion INR | -57.104% |
| Venus Remedies Limited | 284.9 Million INR | -2061.47% |
| ZIM Laboratories Limited | 172.46 Million INR | -3470.716% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -716.152% |
| Par Drugs and Chemicals Limited | 145.01 Million INR | -4146.742% |
| Caplin Point Laboratories Limited | 4.57 Billion INR | -34.726% |
| Shilpa Medicare Limited | 318.74 Million INR | -1832.033% |
| Albert David Limited | 754.2 Million INR | -716.52% |
| Ajanta Pharma Limited | 8.16 Billion INR | 24.548% |
| Hester Biosciences Limited | 188.89 Million INR | -3160.204% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -105.082% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 208.536% |
| Gufic Biosciences Limited | 861.35 Million INR | -614.942% |
| Windlas Biotech Limited | 581.87 Million INR | -958.346% |
| Procter & Gamble Health Limited | 2 Billion INR | -206.409% |
| Aarey Drugs & Pharmaceuticals Limited | 46.83 Million INR | -13048.244% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 6888.364% |
| Granules India Limited | 4.05 Billion INR | -51.938% |
| Aarti Drugs Limited | 1.71 Billion INR | -259.25% |
| Bal Pharma Limited | 73.92 Million INR | -8230.673% |
| Alkem Laboratories Limited | 17.95 Billion INR | 65.707% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 93.569% |
| Lincoln Pharmaceuticals Limited | 933.04 Million INR | -560.008% |
| Medicamen Biotech Limited | 109.31 Million INR | -5533.702% |
| Unichem Laboratories Limited | -704.74 Million INR | 973.822% |
| Bafna Pharmaceuticals Limited | 73.47 Million INR | -8280.898% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -86733.051% |
| Valiant Laboratories Limited | 3.19 Million INR | -192584.606% |
| Orchid Pharma Limited | 921.66 Million INR | -568.16% |
| Medico Remedies Limited | 82.9 Million INR | -7327.662% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | -46.289% |
| Ipca Laboratories Limited | 5.47 Billion INR | -12.509% |
| Brooks Laboratories Limited | -195.91 Million INR | 3243.238% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -2332.706% |
| Piramal Enterprises Limited | -16.83 Billion INR | 136.579% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 62.821% |
| NATCO Pharma Limited | 13.88 Billion INR | 55.642% |
| Suven Life Sciences Limited | -1.05 Billion INR | 686.069% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 3221.49% |
| Strides Pharma Science Limited | -706.14 Million INR | 972.093% |
| Indoco Remedies Limited | 984.6 Million INR | -525.451% |
| Alpa Laboratories Limited | 167.76 Million INR | -3570.73% |
| Lasa Supergenerics Limited | -217.3 Million INR | 2933.884% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 259.039% |